Atrial Fibrillation (AF)NCT07745543
Redo-Pulmonary Vein Isolation With Versus Without Posterior Wall Ablation - The REDO-PIFPAF-PFA Study
A study testing Pulmonary vein isolation with posterior wall ablation and Pulmonary vein isolation without posterior wall ablation in people with Atrial Fibrillation (AF), run by University Hospital, Basel, Switzerland at 5 sites in Switzerland.
Trial summary
The study will compare two ablation strategies in patients with paroxysmal or persistent atrial fibrillation undergoing repeat ablation using pulsed-field ablation: redo pulmonary vein isolation only versus redo pulmonary vein isolation with added posterior wall ablation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation (AF)
- What is being tested?
- Pulmonary vein isolation with posterior wall ablation and Pulmonary vein isolation without posterior wall ablation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 270 participants
- Where
- 5 sitesSwitzerland
- Study dates
- Aug 2026to Jul 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Documented recurrence of paroxysmal or persistent AF following single prior catheter ablation with PVI, confirmed by 12-lead ECG, Holter monitoring, or ICM within the last 2 years.
- Candidate for repeat catheter ablation according to current European Society of Cardiology (ESC) AF management guidelines.
- Continuous oral anticoagulation with a vitamin K antagonist or non-vitamin K oral anticoagulant (NOAC) for ≥ 4 weeks prior to the ablation, or transoesophageal echocardiography (TEE) and/or cardiac computed tomography (CT) within 48 hours before the procedure excluding LA thrombus.
- Age ≥ 18 years at the time of informed consent.
- Written informed consent obtained prior to any study-related procedures.
Who cannot join
- Previous LA surgery
- > 1 prior LA ablation
- LA ablation outside of the PVs in the first LA ablation
- LA diameter >60 mm in the parasternal long axis
- Patients in persistent AF lasting >3 years
- AF due to reversible causes (e.g. hyperthyroidism, cardiothoracic surgery)
Show all 27Show fewer
- Pre-existing PV stenosis or PV stent
- Pre-existing hemidiaphragmatic paralysis
- Contraindication to anticoagulation or radiocontrast materials
- Prior mitral valve surgery
- Severe mitral regurgitation or moderate/severe mitral stenosis
- Myocardial infarction during the 3-month period preceding the consent date
- Ongoing triple antithrombotic/anticoagulation therapy
- Cardiac surgery during the 3-month interval preceding the informed consent date or scheduled cardiac surgery/transcatheter aortic valve implantation procedure
- Significant congenital heart defect (including atrial septal defects or PV abnormalities but not including a patent foramen ovale)
- New York Heart Association (NYHA) class III or IV congestive heart failure
- Left ventricular ejection fraction (LVEF) <35%
- Hypertrophic cardiomyopathy or left septal wall thickness >1.5 cm
- Significant chronic kidney disease (eGFR <30 ml/min)
- Uncontrolled hyperthyroidism
- Cerebral ischemic event (stroke or TIA) during the 6-month interval preceding the informed consent date
- Ongoing systemic infections
- Cardiac amyloidosis
- Pregnancy (to exclude pregnancy a blood test (HCG) is performed in women < 50 years before inclusion)
- Life expectancy less than one year per physician opinion
- Currently participating in any other clinical trial, which may confound the results of this trial.
- Unwilling or unable to comply fully with the study procedures and FU.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
Switzerland5 sites
University Hospital Basel
Basel, 4031
Patrick Badertscher, PD Dr. med., +4161 556 58 23, patrick.badertscher@usb.ch
Patrick Badertscher, PD Dr. med.
Bern University Hospital
Bern, 3010
Tobias Reichlin, Prof. Dr., +41 31 632 21 11, tobias.reichlin@insel.ch
Tobias Reichlin, Prof. Dr.
University Hospital Lausanne
Lausanne, 1011
Patrizio Pascale, PD Dr. med., +41 21 314 48 00, patrizio.pascale@chuv.ch
Patrizio Pascale, PD Dr. med.
Cantonal Hospital of St. Gallen
Sankt Gallen, 9007
Florian Franzeck, Dr. med., +41 71 494 10 51, florian.franzeck@h-och.ch
Florian Franzeck, Dr. med.
University Hospital Zurich,
Zurich, 8091
Alexander Breitenstein, Prof. Dr., +41 44 255 20 99, alexander.breitenstein@usz.ch
Alexander Breitenstein, Prof. Dr.
About this study
Official title: Redo-Pulmonary Vein Isolation Using Pulsed-Field Ablation With Versus Without Posterior Wall Ablation in Patients With Symptomatic Atrial Fibrillation: A Multi-Centre Randomized Clinical Trial: The REDO-PIFPAF-PFA Study
The study will compare two ablation strategies in patients with paroxysmal or persistent atrial fibrillation undergoing repeat ablation using pulsed-field ablation: redo pulmonary vein isolation only versus redo pulmonary vein isolation with added posterior wall ablation.
Read the detailed description
In most patients, recurrence after ablation is caused by reconnection of previously isolated pulmonary veins (PV). However, atrial fibrillation (AF) recurrence may also result from progressive atrial remodelling, structural disease progression, and triggers originating outside the PVs. While there are multiple randomized controlled trials and clear recommendations for de novo ablations, there is a notable lack of studies and guideline recommendations for redo ablation procedures. Current practice therefore remains heterogeneous, and optimal lesion sets in the redo setting are not defined. The study aims to address this deficiency by undertaking a randomised comparison of two strategies that have already been adopted.
- Conditions
- Atrial Fibrillation (AF)
- Being tested
- Pulmonary vein isolation with posterior wall ablation, Pulmonary vein isolation without posterior wall ablation
- Keywords
- Pulmonary vein isolation, Pulsed field albation, posterior wall ablation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulmonary vein isolation with posterior wall ablationProcedure or surgery
Redo-pulmonary vein isolation with left atrial posterior wall ablation using pulsed-field ablation technology. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
Pulmonary vein isolation without posterior wall ablationProcedure or surgery
Redo-pulmonary vein isolation without left atrial posterior wall ablation using pulsed-field ablation technology. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Arm | Experimental | Not described Receives: Procedure: Pulmonary vein isolation with posterior wall ablation |
| Control Arm | Active comparator | Not described Receives: Procedure: Pulmonary vein isolation without posterior wall ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first recurrence of any atrial tachyarrhythmia day 61-365
Time to first recurrence of atrial tachyarrhythmia (atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT)) between day 61 and 365 post ablation as detected on an implantable cardiac monitor (ICM).
AF, AFL or AT will be defined as an episode of at least 120 seconds (the shortest-duration episode that could be programmed for detection on the implantable cardiac monitor) with a continuous atrial arrhythmia of at least 30 seconds.
Measured: Day 61-365 post-ablation
Secondary outcomes (35)
Treatment-emergent adverse events: Cardiac tamponade requiring drainage
Number of patients with cardiac tamponade requiring drainage after PVI
Measured: Day 0-90 post-ablation
Treatment-emergent adverse events: Persistent phrenic nerve palsy lasting >24 hours
Number of patients with persistent phrenic nerve palsy lasting >24 hours after PVI
Measured: Day 0-90 post-ablation
Treatment-emergent adverse events: Serious vascular complication requiring intervention
Number of patients with serious vascular complications requiring intervention after PVI
Measured: Day 0-90 post-ablation
Treatment-emergent adverse events: Stroke or TIA
Number of patients with stroke or TIA after PVI
Measured: Day 0-90 post-ablation
Treatment-emergent adverse events: Atrioesophageal fistula
Number of patients with atrioesophageal fistula after PVI
Measured: Day 0-90 post-ablation
Treatment-emergent adverse events: Death
Number of patients with fatal outcome/death after PVI
Measured: Day 0-90 post-ablation
Total procedure time
Procedural endpoint; [min]
Measured: Day 0, during procedure
Total left atrial indwelling time
Procedural endpoint; [min]
Measured: Day 0, during procedure
Total fluoroscopy time
Procedural endpoint; [min]
Measured: Day 0, during procedure
Total radiation dose
Procedural endpoint; Calculated by multiplying the absorbed radiation dose (air kerma) by the cross-sectional area of the X-ray beam [cG*cm2]
Measured: Day 0, during procedure
Change in hs-troponin on Day 1 post-ablation compared with pre-procedural hs-troponin
Procedural endpoint; [ng/L]
Measured: Pre-procedural (day -1 or day 0) to day 1 post-ablation
Post-ablation 3D-EAM: Assessment of atrial low-voltage/scar
Procedural endpoint; Presence and extend of atrial low-voltage/scar will be assessed on 3D-EAM (three dimensional electroanatomical mapping.). Low-voltage areas will be identified on the basis of bipolar voltage mapping according to pre-specified mapping settings (rhythm during mapping, catheter type, point density, filtering) and recorded as (i) presence/absence and (ii) quantified surface area (cm²) within predefined left atrial regions (including posterior wall; optional: anterior wall; overall left atrium).
Measured: Day 0, shortly after ablation
Post-ablation 3D-EAM: Proportion of isolated veins
Procedural endpoint
Measured: Day 0, shortly after ablation
Post-ablation 3D-EAM: Proportion of isolated carinas
Procedural endpoint
Measured: Day 0, shortly after ablation
Post-ablation 3D-EAM: Lesion size
Procedural endpoint
Measured: Day 0, shortly after ablation
Post-ablation 3D-EAM: Posterior wall ablation success rate
Procedural endpint; experimental group only
Measured: Day 0, shortly after ablation
Time to first recurrence of any atrial tachyarrhythmia in patients with left atrial posterior wall scar and posterior wall ablation versus without posterior wall ablation
Secondary endpoint during follow-up
Measured: up to 3 years
Arrhythmia burden for each participant between days 0-60 evaluated based on continuous ICM (Implantable cardiac monitor)
Secondary endpoint during follow-up
Measured: Day 0-60 post-ablation
Arrhythmia burden for each participant between days 61 and 365 evaluated based on continuous ICM
Secondary endpoint during follow-up
Measured: Day 61-365 post-ablation
Arrhythmia burden for each participant between days 365 until explantation or end of life (EOL) of the ICM
Secondary endpoint during follow-up
Measured: Day 365 post-ablation to explantation of ICM or end of life of ICM (up to 4 years after implantation of ICM)
Correlation of AF burden to symptoms and quality of life (QoL) changes
Secondary endpoint during follow-up; Quality of life will be measured with the EQ-5D-5L questionnaire where higher scores mean better outcomes; Symptoms will be measured with the AFEQT (Atrial Fibrillation Effect on Quality-of-life) questionnaire where higher scores mean worse outcomes.
Measured: Day 0-365 post-ablation
Reduction of AF burden by > 90% post ablation procedure
Secondary endpoint during follow-up
Measured: up to 3 years
Comparison of the prevalence of the type of arrhythmia recurrence during FU being atrial fibrillation or organized atrial arrhythmias (atrial flutter or atrial tachycardia)
Secondary endpoint during follow-up
Measured: up to 3 years
Time to first recurrence of atrial tachyarrhythmia between days 61 and 365 in patients with presence of scar on the posterior wall based on the pre-ablation voltage map versus patients with no scar on the posterior wall evaluated based on continuous ICM
Secondary endpoint during follow-up
Measured: up to 1 year
Prevalence of persistent or paroxysmal atrial fibrillation
Secondary endpoint during follow-up
Measured: up to 3 years
Average heart rate
Secondary endpoint during follow-up; as recorded by the ICM in months 1, 2 and 3 after ablation
Measured: Months 1, 2 and 3 post-ablation
Hospital or emergency room admission due to documented recurrence of atrial arrhythmias
Incidence rate
Measured: up to 3 years
Repeat ablation procedure due to documented recurrence of atrial arrhythmias
Incidence rate
Measured: up to 3 years
Reinitiation or continuation of antiarrhythmic drug therapy
Incidence rate
Measured: up to 3 years
Electrical cardioversion due to recurrence
Incidence rate
Measured: up to 3 years
Number of reconnected veins evaluated during redo procedures
Secondary endpoint during follow up; sites of reconnection and size of antral scar area evaluated during redo procedures
Measured: During redo procedures between day 1 to 36 months post-ablation
Number of reconnected posterior walls evaluated during redo procedures
Secondary endpoint during follow-up; sites of reconnection and size of the scar area evaluated during redo procedures
Measured: During redo procedures between day 1 to 36 months post-ablation
Evolution of QoL
The Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire is a 20-item, disease-specific tool used to measure how atrial fibrillation impacts a patient's daily life. Results are calculated on a scale from 0 (worst possible quality of life) to 100 (best possible quality of life).
The EQ-5D-5L is a standardized, generic questionnaire used to measure health-related quality of life. The patient rates health on the current day across 5 areas: mobility, self-care; usual activities; Pain/discomfort; anxiety/depression. For each dimension, the patient chooses one of 5 severity levels: No problems;Slight problems;Moderate problems;Severe problems;Extreme problems / Unable to.
Measured: Day 90 and day 365 post-ablation
Stroke or TIA (Transient ischemic attack)
Incidence rate
Measured: 3, 12, 24 and 36 months
All-cause death
Incidence rate; cardiovascular or non-cardiovascular
Measured: after 3, 12, 24 and 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2026
- Study startAug 2026 (estimated)
- Primary completionJul 2031 (estimated)
- Study completionJul 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Multi-centre, randomized controlled superiority trial with a parallel cohort arm
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 270 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- Swiss Heart Foundation, Boston Scientific Corporation
- Responsible party
- Sponsor
- Investigators
- Patrick Badertscher, PD Dr. med., Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07745543
- Sponsor's protocol ID
- 2026-00465; kt25badertscher2
- Status last verified
- Jul 2026
- First submitted
- 29 Jul 2026
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Redo-Pulmonary Vein Isolation Using Pulsed-Field Ablation With Versus Without Posterior Wall Ablation in Patients With Symptomatic Atrial Fibrillation: A Multi-Centre Randomized Clinical Trial: The REDO-PIFPAF-PFA Study
- ClinicalTrials.gov ID
- NCT07745543
- Acronym / sponsor ID
- 2026-00465; kt25badertscher2
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- Pulmonary vein isolation, Pulsed field albation, posterior wall ablation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 270 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Collaborators
- Swiss Heart Foundation, Boston Scientific Corporation
- Study start
- Aug 2026 (estimated)
- Primary completion
- Jul 2031 (estimated)
- Study completion
- Jul 2031 (estimated)
- First posted
- 4 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will compare two ablation strategies in patients with paroxysmal or persistent atrial fibrillation undergoing repeat ablation using pulsed-field ablation: redo pulmonary vein isolation only versus redo pulmonary vein isolation with added posterior wall ablation.
Detailed description
In most patients, recurrence after ablation is caused by reconnection of previously isolated pulmonary veins (PV). However, atrial fibrillation (AF) recurrence may also result from progressive atrial remodelling, structural disease progression, and triggers originating outside the PVs. While there are multiple randomized controlled trials and clear recommendations for de novo ablations, there is a notable lack of studies and guideline recommendations for redo ablation procedures. Current practice therefore remains heterogeneous, and optimal lesion sets in the redo setting are not defined. The study aims to address this deficiency by undertaking a randomised comparison of two strategies that have already been adopted.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Multi-centre, randomized controlled superiority trial with a parallel cohort arm
| Arm | Type | Receives |
|---|---|---|
| Intervention Arm | Experimental | Procedure: Pulmonary vein isolation with posterior wall ablation |
| Control Arm | Active comparator | Procedure: Pulmonary vein isolation without posterior wall ablation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Documented recurrence of paroxysmal or persistent AF following single prior catheter ablation with PVI, confirmed by 12-lead ECG, Holter monitoring, or ICM within the last 2 years.
- Candidate for repeat catheter ablation according to current European Society of Cardiology (ESC) AF management guidelines.
- Continuous oral anticoagulation with a vitamin K antagonist or non-vitamin K oral anticoagulant (NOAC) for ≥ 4 weeks prior to the ablation, or transoesophageal echocardiography (TEE) and/or cardiac computed tomography (CT) within 48 hours before the procedure excluding LA thrombus.
- Age ≥ 18 years at the time of informed consent.
- Written informed consent obtained prior to any study-related procedures.
Key exclusion criteria (27 listed)
- Previous LA surgery
- > 1 prior LA ablation
- LA ablation outside of the PVs in the first LA ablation
- LA diameter >60 mm in the parasternal long axis
- Patients in persistent AF lasting >3 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulmonary vein isolation with posterior wall ablationRedo-pulmonary vein isolation with left atrial posterior wall ablation using pulsed-field ablation technology. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring. | Procedure or surgery | Intervention Arm |
| Pulmonary vein isolation without posterior wall ablationRedo-pulmonary vein isolation without left atrial posterior wall ablation using pulsed-field ablation technology. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring. | Procedure or surgery | Control Arm |
Primary outcome
Time to first recurrence of any atrial tachyarrhythmia day 61-365
Time frame: Day 61-365 post-ablation
Time to first recurrence of atrial tachyarrhythmia (atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT)) between day 61 and 365 post ablation as detected on an implantable cardiac monitor (ICM). AF, AFL or AT will be defined as an episode of at least 120 seconds (the shortest-duration episode that could be programmed for detection on the implantable cardiac monitor) with a continuous atrial arrhythmia of at least 30 seconds.
35 secondary outcomes
Treatment-emergent adverse events: Cardiac tamponade requiring drainage
Time frame: Day 0-90 post-ablation
Treatment-emergent adverse events: Persistent phrenic nerve palsy lasting >24 hours
Time frame: Day 0-90 post-ablation
Treatment-emergent adverse events: Serious vascular complication requiring intervention
Time frame: Day 0-90 post-ablation
Treatment-emergent adverse events: Stroke or TIA
Time frame: Day 0-90 post-ablation
Treatment-emergent adverse events: Atrioesophageal fistula
Time frame: Day 0-90 post-ablation
Treatment-emergent adverse events: Death
Time frame: Day 0-90 post-ablation
Total procedure time
Time frame: Day 0, during procedure
Total left atrial indwelling time
Time frame: Day 0, during procedure
Total fluoroscopy time
Time frame: Day 0, during procedure
Total radiation dose
Time frame: Day 0, during procedure
Change in hs-troponin on Day 1 post-ablation compared with pre-procedural hs-troponin
Time frame: Pre-procedural (day -1 or day 0) to day 1 post-ablation
Post-ablation 3D-EAM: Assessment of atrial low-voltage/scar
Time frame: Day 0, shortly after ablation
Post-ablation 3D-EAM: Proportion of isolated veins
Time frame: Day 0, shortly after ablation
Post-ablation 3D-EAM: Proportion of isolated carinas
Time frame: Day 0, shortly after ablation
Post-ablation 3D-EAM: Lesion size
Time frame: Day 0, shortly after ablation
Post-ablation 3D-EAM: Posterior wall ablation success rate
Time frame: Day 0, shortly after ablation
Time to first recurrence of any atrial tachyarrhythmia in patients with left atrial posterior wall scar and posterior wall ablation versus without posterior wall ablation
Time frame: up to 3 years
Arrhythmia burden for each participant between days 0-60 evaluated based on continuous ICM (Implantable cardiac monitor)
Time frame: Day 0-60 post-ablation
Arrhythmia burden for each participant between days 61 and 365 evaluated based on continuous ICM
Time frame: Day 61-365 post-ablation
Arrhythmia burden for each participant between days 365 until explantation or end of life (EOL) of the ICM
Time frame: Day 365 post-ablation to explantation of ICM or end of life of ICM (up to 4 years after implantation of ICM)
Correlation of AF burden to symptoms and quality of life (QoL) changes
Time frame: Day 0-365 post-ablation
Reduction of AF burden by > 90% post ablation procedure
Time frame: up to 3 years
Comparison of the prevalence of the type of arrhythmia recurrence during FU being atrial fibrillation or organized atrial arrhythmias (atrial flutter or atrial tachycardia)
Time frame: up to 3 years
Time to first recurrence of atrial tachyarrhythmia between days 61 and 365 in patients with presence of scar on the posterior wall based on the pre-ablation voltage map versus patients with no scar on the posterior wall evaluated based on continuous ICM
Time frame: up to 1 year
Prevalence of persistent or paroxysmal atrial fibrillation
Time frame: up to 3 years
Average heart rate
Time frame: Months 1, 2 and 3 post-ablation
Hospital or emergency room admission due to documented recurrence of atrial arrhythmias
Time frame: up to 3 years
Repeat ablation procedure due to documented recurrence of atrial arrhythmias
Time frame: up to 3 years
Reinitiation or continuation of antiarrhythmic drug therapy
Time frame: up to 3 years
Electrical cardioversion due to recurrence
Time frame: up to 3 years
Number of reconnected veins evaluated during redo procedures
Time frame: During redo procedures between day 1 to 36 months post-ablation
Number of reconnected posterior walls evaluated during redo procedures
Time frame: During redo procedures between day 1 to 36 months post-ablation
Evolution of QoL
Time frame: Day 90 and day 365 post-ablation
Stroke or TIA (Transient ischemic attack)
Time frame: 3, 12, 24 and 36 months
All-cause death
Time frame: after 3, 12, 24 and 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- Individual participant dataSharing planned: Yes
Related trials for Atrial Fibrillation (AF)
Not yet recruiting
A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter
Atrial Fibrillation
RecruitingPhase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Atrial Fibrillation
Recruiting
Structured Treatment and Resource Efficiency Assessment With Lean Six Sigma Integration for Pulmonary Vein Isolation
Atrial Fibrillation (AF)
Active, not recruitingObservational study
Resumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation
Atrial Fibrillation (AF), Major Gastrointestinal Bleeding (MGIB)
Active, not recruiting
VOLT CE Mark Study
Atrial Arrhythmia, Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Patrick Badertscher, PD Dr. med. principal investigator
University Hospital, Basel, Switzerland
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pulmonary vein isolation with posterior wall ablation and Pulmonary vein isolation without posterior wall ablation in people with Atrial Fibrillation (AF), run by University Hospital, Basel, Switzerland at 5 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patrick Badertscher, PD Dr. med. (+4161 556 58 23, patrick.badertscher@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first recurrence of any atrial tachyarrhythmia day 61-365 (time frame: Day 61-365 post-ablation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.